Collaboration with CSEM will speed up identification of suitable soluble TCR candidates Engimmune’s executive team will be presenting at Biotech Showcase in San Francisco in January Basel, Switzerland, December 13, 2023 – Engimmune Therapeutics AG (“Engimmune”), a world-class developer of soluble T-cell receptor drugs (‘TCRs’) to treat solid tumours, is pleased to announce that it […]